0001638599-20-000977.txt : 20201217
0001638599-20-000977.hdr.sgml : 20201217
20201217160616
ACCESSION NUMBER: 0001638599-20-000977
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201215
FILED AS OF DATE: 20201217
DATE AS OF CHANGE: 20201217
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Patel Mahesh V.
CENTRAL INDEX KEY: 0001579872
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36357
FILM NUMBER: 201396173
MAIL ADDRESS:
STREET 1: C/O LIPOCINE, INC.
STREET 2: 675 ARAPEEN DRIVE, STE. 202
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84108
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lipocine Inc.
CENTRAL INDEX KEY: 0001535955
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 990370688
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 675 ARAPEEN DRIVE, SUITE 202
CITY: SALT LAKE CITY
STATE: X1
ZIP: 84108
BUSINESS PHONE: 801 994 7383
MAIL ADDRESS:
STREET 1: 675 ARAPEEN DRIVE, SUITE 202
CITY: SALT LAKE CITY
STATE: X1
ZIP: 84108
FORMER COMPANY:
FORMER CONFORMED NAME: MARATHON BAR CORP
DATE OF NAME CHANGE: 20111130
4
1
doc4_6960.xml
PRIMARY DOCUMENT
X0306
4
2020-12-15
0
0001535955
Lipocine Inc.
LPCN
0001579872
Patel Mahesh V.
675 ARAPEEN DRIVE
SUITE 202
SALT LAKE CITY
UT
84010
1
1
0
0
Chief Executive Officer
Common Stock
2020-12-16
4
M
0
45000
0
A
1243090
D
Common Stock
2020-12-16
4
S
0
15000
1.35
D
1228090
D
Stock Option (Right to Buy)
1.37
2020-12-15
4
A
0
375000
1.37
A
2021-12-15
2030-12-15
Common Stock
375000
375000
D
Restricted Stock Unit
0
2020-12-16
4
M
0
45000
0
A
2020-12-16
2027-01-25
Common Stock
45000
45000
D
Subject to vesting whereby 1/3 of the shares subject to the award will vest on the one year anniversary of December 15, 2021, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorata basis over the following two years.
Subject to vesting whereby 1/4 of the shares subject to the award will vest on December 31, 2017 and the remaining 3/4 of the shares subject to the award will vest on the receipt by the Company of FDA approval of TLANDO.
Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
/s/Mahesh V Patel
2020-12-17